Geneoscopy is a St. Louis life-sciences company building noninvasive diagnostics that read RNA biomarkers in stool to prevent, detect, and treat gastrointestinal disease. Its flagship product, ColoSense, is the first FDA-approved multi-target stool RNA (mt-sRNA) test for colorectal cancer screening in adults 45 and older, designed to lift screening compliance by replacing the colonoscopy prep and the clinic visit with a kit that arrives in the mail. Founded by siblings Andrew and Erica Barnell, the company is extending its RNA platform from cancer screening into inflammatory bowel disease.
GentiBio is a clinical-stage biotechnology company in Cambridge, Massachusetts building engineered regulatory T cell (EngTreg) therapies designed to restore immune tolerance and durably treat autoimmune, autoinflammatory, alloimmune, and allergic diseases. Spun out of research from Seattle Children's, Benaroya Research Institute, and MIGAL Galilee Research Institute, the company combines gene editing of FOXP3 with a modular Treg engineering and manufacturing platform. Its lead program, GNTI-122, is an autologous antigen-specific Treg therapy for recently diagnosed type 1 diabetes now in a Phase 1 trial (POLARIS). GentiBio has raised roughly $177M and signed a partnership with Bristol Myers Squibb worth up to $1.9B in potential milestones.
Oshi Health is a virtual-first gastrointestinal care clinic that gives the roughly one in four Americans living with digestive disorders fast access to a coordinated team of GI providers, registered dietitians, behavioral health specialists, and care coordinators. Available in all 50 states as an in-network benefit, Oshi pairs unlimited virtual visits and messaging with evidence-based, whole-person treatment - an approach a national health plan's analysis tied to 92% symptom improvement, 98% patient satisfaction, and more than $10,000 in medical cost savings per patient over six months.